Migraine is the most common neurological disorder and can be associated with a聽high degree of disability. In addition to non-pharmacological approaches to reduce migraine frequency, pharmacological migraine preventatives are available. Evidence-based guidelines from the German Migraine and Headache Society (DMKG), and German Society for Neurology (DGN), Austrian Headache Society (脰KSG), and Swiss Headache Society (SKG) are available for indication and application. For therapy-relevant questions such as the duration of a聽pharmacological migraine prevention, no conclusions can be drawn from currently available study data. The aim of this review is to present a聽therapy consensus statement that integrates the current data situation and, where data are lacking, expert opinions. The resulting current recommendations on the duration of therapy for pharmacological migraine prophylaxis are shown here.
Browse by Audience
Skip to content